{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:08:33Z","timestamp":1791320913339,"version":"4.3.1"},"reference-count":69,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Russian Science Foundation","award":["21-65-00004"],"award-info":[{"award-number":["21-65-00004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Early efforts to identify tumor-associated antigens over the last decade have provided unique cancer epitopes for targeted cancer therapy. MAGE-A proteins are a subclass of cancer\/testis (CT) antigens that are presented on the cell surface by MHC class I molecules as an immune-privileged site. This is due to their restricted expression to germline cells and a wide range of cancers, where they are associated with resistance to chemotherapy, metastasis, and cancer cells with an increasing potential for survival. This makes them an appealing candidate target for designing an effective and specific immunotherapy, thereby suggesting that targeting oncogenic MAGE-As with cancer vaccination, adoptive T-cell transfer, or a combination of therapies would be promising. In this review, we summarize and discuss previous and ongoing (pre-)clinical studies that target these antigens, while bearing in mind the benefits and drawbacks of various therapeutic strategies, in order to speculate on future directions for MAGE-A-specific immunotherapies.<\/jats:p>","DOI":"10.3390\/cancers15061779","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T05:53:44Z","timestamp":1678859624000},"page":"1779","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy?"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4395-5822","authenticated-orcid":false,"given":"Alaa","family":"Alsalloum","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia"},{"name":"Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Shevchenko","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7366-7768","authenticated-orcid":false,"given":"Sergey","family":"Sennikov","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia"},{"name":"Department of Immunology, V. Zelman Institute for Medicine and Psychology, Novosibirsk State University, 630090 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.3748\/wjg.v24.i48.5418","article-title":"Colorectal Cancer Vaccines: Tumor-Associated Antigens vs Neoantigens","volume":"24","author":"Wagner","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.18632\/oncotarget.4694","article-title":"Oncogenic Cancer\/Testis Antigens: Prime Candidates for Immunotherapy","volume":"6","author":"Gjerstorff","year":"2015","journal-title":"Oncotarget"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4251\/wjgo.v7.i12.492","article-title":"Targeting Cancer Testis Antigens for Biomarkers and Immunotherapy in Colorectal Cancer: Current Status and Challenges","volume":"7","author":"Suri","year":"2015","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jcp.10215","article-title":"Cancer\/Testis-Associated Genes: Identification, Expression Profile, and Putative Function","volume":"194","author":"Zendman","year":"2003","journal-title":"J. Cell. Physiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20422","DOI":"10.1073\/pnas.0810777105","article-title":"Genome-Wide Analysis of Cancer\/Testis Gene Expression","volume":"105","author":"Hofmann","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.canlet.2004.07.028","article-title":"Expression of Cancer\/Testis (CT) Antigens in Chinese Hepatocellular Carcinoma and Its Correlation with Clinical Parameters","volume":"219","author":"Peng","year":"2005","journal-title":"Cancer Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1073\/pnas.0915050107","article-title":"Expression of Cancer Testis Antigen CT45 in Classical Hodgkin Lymphoma and Other B-Cell Lymphomas","volume":"107","author":"Chen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1475-2867-5-4","article-title":"Cancer\/Testis Antigens and Gametogenesis: A Review and \u201cBrain-Storming\u201d Session","volume":"5","author":"Kalejs","year":"2005","journal-title":"Cancer Cell Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma","volume":"254","author":"Traversari","year":"1991","journal-title":"Science"},{"key":"ref_10","first-page":"5544","article-title":"An Overview of the MAGE Gene Family with the Identification of All Human Members of the Family","volume":"61","author":"Chomez","year":"2001","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2015.08.002","article-title":"The MAGE Protein Family and Cancer","volume":"37","author":"Weon","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/jnr.10160","article-title":"The MAGE Proteins: Emerging Roles in Cell Cycle Progression, Apoptosis, and Neurogenetic Disease","volume":"67","author":"Barker","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.molcel.2010.08.029","article-title":"MAGE-RING Protein Complexes Comprise a Family of E3 Ubiquitin Ligases","volume":"39","author":"Doyle","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1038\/s41467-020-18708-x","article-title":"Structural Basis for Substrate Recognition and Chemical Inhibition of Oncogenic MAGE Ubiquitin Ligases","volume":"11","author":"Yang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.cell.2015.01.034","article-title":"Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase","volume":"160","author":"Pineda","year":"2015","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25182","DOI":"10.1038\/srep25182","article-title":"Consequences of Point Mutations in Melanoma-Associated Antigen 4 (MAGE-A4) Protein: Insights from Structural and Biophysical Studies","volume":"6","author":"Hagiwara","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ijc.2910630313","article-title":"Expression of MAGE Genes in Primary and Metastatic Cutaneous Melanoma","volume":"63","author":"Brasseur","year":"1995","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00000658-199608000-00011","article-title":"Expression of MAGE Genes in Human Colorectal Carcinoma","volume":"224","author":"Mori","year":"1996","journal-title":"Ann. Surg."},{"key":"ref_19","first-page":"6682","article-title":"MAGE-A Gene Expression Pattern in Primary Breast Cancer","volume":"61","author":"Otte","year":"2001","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Daudi, S., Eng, K.H., Mhawech-Fauceglia, P., Morrison, C., Miliotto, A., Beck, A., Matsuzaki, J., Tsuji, T., Groman, A., and Gnjatic, S. (2014). Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104099"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3892\/ijmm.2012.896","article-title":"Pattern of Cancer\/Testis Antigen Expression in Lung Cancer Patients","volume":"29","author":"Kim","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1158\/1078-0432.CCR-05-1203","article-title":"Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non\u2013Small Cell Lung Cancer","volume":"11","author":"Gure","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_23","first-page":"541","article-title":"High Expression of MAGE-A9 in Tumor and Stromal Cells of Non-Small Cell Lung Cancer Was Correlated with Patient Poor Survival","volume":"8","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1038\/srep06625","article-title":"High Expression of MAGE-A9 Correlates with Unfavorable Survival in Hepatocellular Carcinoma","volume":"4","author":"Gu","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11160","DOI":"10.1073\/pnas.0510834103","article-title":"MAGE-A Tumor Antigens Target P53 Transactivation Function through Histone Deacetylase Recruitment and Confer Resistance to Chemotherapeutic Agents","volume":"103","author":"Monte","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1158\/0008-5472.CAN-07-1478","article-title":"MAGE-A, MMage-b, and MAGE-C Proteins Form Complexes with KAP1 and Suppress P53-Dependent Apoptosis in MAGE-Positive Cell Lines","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Schwarzenbach, H., Eichelser, C., Steinbach, B., Tadewaldt, J., Pantel, K., Lobanenkov, V., and Loukinov, D. (2014). Differential Regulation of MAGE-A1 Promoter Activity by BORIS and Sp 1, Both Interacting with the TATA Binding Protein. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-796"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1158\/1541-7786.MCR-05-0229","article-title":"Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells","volume":"4","author":"Wischnewski","year":"2006","journal-title":"Mol. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1128\/MCB.19.11.7327","article-title":"DNA Methylation Is the Primary Silencing Mechanism for a Set of Germ Line- and Tumor-Specific Genes with a CpG-Rich Promoter","volume":"19","author":"Lurquin","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/BF00176446","article-title":"Involvement of Two Ets Binding Sites in the Transcriptional Activation of the MAGE1 Gene","volume":"42","author":"Courtois","year":"1995","journal-title":"Immunogenetics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.abb.2011.01.007","article-title":"Identification of Novel Small Molecules That Inhibit Protein-Protein Interactions between MAGE and KAP-1","volume":"508","author":"Bhatia","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1073\/pnas.93.14.7149","article-title":"The Activation of Human Gene MAGE-1 in Tumor Cells Is Correlated with Genome-Wide Demethylation","volume":"93","author":"Faraoni","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","first-page":"1766","article-title":"Expression of the MAGE-1 Tumor Antigen Is up-Regulated by the Demethylating Agent 5-Aza-2\u2032-Deoxycytidine","volume":"54","author":"Weber","year":"1994","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/(SICI)1097-0215(19980812)77:4<538::AID-IJC11>3.0.CO;2-2","article-title":"Estimation of the Frequencies of Anti-MAGE-3 Cytolytic T-Lymphocyte Precursors in Blood from Individuals without Cancer","volume":"77","author":"Chaux","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.0.CO;2-7","article-title":"Expression of the MAGE Gene Family in Human Hepatocellular Carcinoma","volume":"85","author":"Tahara","year":"1999","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2018.04.009","article-title":"MAGE-A Antigens as Targets for Cancer Immunotherapy","volume":"67","author":"Schooten","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of Immunostimulant AS15 for Active Immunization with MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 Immunotherapeutic as Adjuvant Therapy for Patients with Resected, MAGE-A3-Positive, Stage III Melanoma (DERMA): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e000203","DOI":"10.1136\/esmoopen-2017-000203","article-title":"Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with Dacarbazine in Patients with MAGE-A3-Positive Metastatic Cutaneous Melanoma: An Open Phase I\/II Study with a First Assessment of a Predictive Gene Signature","volume":"2","author":"Grob","year":"2017","journal-title":"ESMO Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resected MAGE-A3-Positive Non-Small-Cell Lung Cancer (MAGRIT): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1158\/1078-0432.CCR-18-1013","article-title":"A Designer Cross-Reactive DNA Immunotherapeutic Vaccine That Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy","volume":"24","author":"Duperret","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00432-013-1552-8","article-title":"Induction of Antigen-Specific Immune Responses by Dendritic Cells Transduced with a Recombinant Lentiviral Vector Encoding MAGE-A3 Gene","volume":"140","author":"Lin","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.vaccine.2013.12.049","article-title":"Efficient Lysis of Epithelial Ovarian Cancer Cells by MAGE-A3-Induced Cytotoxic T Lymphocytes Using RAAV-6 Capsid Mutant Vector","volume":"32","author":"Batchu","year":"2014","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/CJI.0b013e31821dcb31","article-title":"Therapeutic Vaccination With an Autologous MRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma","volume":"34","author":"Wilgenhof","year":"2011","journal-title":"J. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1158\/1078-0432.CCR-08-2982","article-title":"Single-Step Antigen Loading and Activation of Dendritic Cells by MRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients","volume":"15","author":"Bonehill","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA Delivery to Dendritic Cells Exploits Antiviral Defence for Cancer Immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1349-7006.2011.02106.x","article-title":"First Clinical Trial of Cancer Vaccine Therapy with Artificially Synthesized Helper\/Killer-Hybrid Epitope Long Peptide of MAGE-A4 Cancer Antigen","volume":"103","author":"Takahashi","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e000329","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and Tumor Antigen MRNA Electroporated Dendritic Cell Vaccination plus Ipilimumab: Link between T-Cell Activation and Clinical Responses in Advanced Melanoma","volume":"8","author":"Claerhout","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer Vaccines as Promising Immuno-Therapeutics: Platforms and Current Progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00262-015-1731-3","article-title":"A Phase I Trial Combining Decitabine\/Dendritic Cell Vaccine Targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for Children with Relapsed or Therapy-Refractory Neuroblastoma and Sarcoma","volume":"64","author":"Krishnadas","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive Cell Therapy for Patients with Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7058","DOI":"10.1158\/1078-0432.CCR-11-1873","article-title":"Improving T-Cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4","volume":"17","author":"Cruz","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1189\/jlb.1209824","article-title":"Genetic Redirection of T Cells for Cancer Therapy","volume":"87","author":"Westwood","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1349-7006.2011.02111.x","article-title":"T-Cell Receptor Gene Therapy Targeting Melanoma-Associated Antigen-A4 Inhibits Human Tumor Growth in Non-Obese Diabetic\/SCID\/\u0393cnull Mice","volume":"103","author":"Shirakura","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-14-1559","article-title":"Adoptive Transfer of MAGE-A4 T-Cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer","volume":"21","author":"Kageyama","year":"2015","journal-title":"Clin. cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular Toxicity and Titin Cross-Reactivity of Affinity-Enhanced T Cells in Myeloma and Melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CJI.0000000000000123","article-title":"Isolation and Characterization of an HLA-DPB1*04: 01-Restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy","volume":"39","author":"Yao","year":"2016","journal-title":"J. Immunother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","article-title":"Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3","volume":"35","author":"Lu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e003581","DOI":"10.1136\/jitc-2021-003581","article-title":"Phase I Clinical Trial Evaluating the Safety and Efficacy of ADP-A2M10 SPEAR T Cells in Patients with MAGE-A10(+) Advanced Non-Small Cell Lung Cancer","volume":"10","author":"Blumenschein","year":"2022","journal-title":"J. Immunother. cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"818679","DOI":"10.3389\/fonc.2022.818679","article-title":"Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors","volume":"12","author":"Hong","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1682381","DOI":"10.1080\/2162402X.2019.1682381","article-title":"Preclinical Evaluation of an Affinity-Enhanced MAGE-A4-Specific T-Cell Receptor for Adoptive T-Cell Therapy","volume":"9","author":"Sanderson","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2020.38.15_suppl.102","article-title":"Phase I Dose Escalation and Expansion Trial to Assess the Safety and Efficacy of ADP-A2M4 SPEAR T Cells in Advanced Solid Tumors","volume":"38","author":"Hong","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/sj.gt.3301570","article-title":"A Phage Display Selected Fab Fragment with MHC Class I-Restricted Specificity for MAGE-A1 Allows for Retargeting of Primary Human T Lymphocytes","volume":"8","author":"Willemsen","year":"2001","journal-title":"Gene Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2020.00257","article-title":"TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens","volume":"11","author":"Akatsuka","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12929-016-0311-y","article-title":"State of the Art in Anti-Cancer MAbs","volume":"24","author":"Chiavenna","year":"2017","journal-title":"J. Biomed. Sci."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/6\/1779\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:55:40Z","timestamp":1760122540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/6\/1779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":69,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["cancers15061779"],"URL":"https:\/\/doi.org\/10.3390\/cancers15061779","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]}}}